Erythromelalgia

Back

Practice Essentials

Erythromelalgia is a rare disorder characterized by burning pain, warmth, and redness, predominantly involving the extremities.[1, 2]  The feet are more frequently involved than the hands. Rarely, non-extremity involvement is seen in areas such as the face and genitals.

A distinction is generally made between primary (idiopathic or genetic) and secondary erythromelalgia (most commonly associated with myeloproliferative disorders), as well as between early- and late-onset disease.[3]

There is no known cure for erythromelalgia and thus symptomatic treatment forms the cornerstone of management. Therapies that are effective for many patients include aspirin, topical agents, and behavioral modifications.

 

Background

The name erythromelalgia is derived from Greek: erythros (“red”), melos (“limb”), and algos (“pain”). Mitchell first described erythromelalgia in the 1870s. Smith and Allen further categorized it in 1938, proposing the term erythermalgia to emphasize the characteristic warmth. They also suggested a distinction between primary (idiopathic) erythromelalgia and secondary erythromelalgia due to underlying neurologic, hematologic, or vascular problems.

Drenth and Michiels distinguished between erythromelalgia and erythermalgia on the basis of responsiveness to aspirin and established the following three categories[4] :

 

Pathophysiology

The first insights into the pathophysiology of erythromelalgia associated with thrombocythemia were gained when skin biopsy samples revealed arteriolar fibrosis and occlusion with platelet thrombi.[5] In this setting, platelets may have abnormal hyperaggregability. Platelet kinetic studies show decreased platelet survival, predominantly due to consumption. Prostaglandins and cyclooxygenase apparently play an important pathogenetic role.

For erythromelalgia not associated with thrombocythemia, the pathophysiology is less clear, but it is known to not involve platelet-mediated inflammation and thrombosis. This is the major reason why Drenth and Michiels distinguished primary erythromelalgia (erythermalgia) from secondary erythromelalgia.[4, 6] Factors postulated to contribute to primary erythromelalgia include the following:

Molecular biology may provide the key to understanding this disorder.[10] Drenth et al examined 5 kindreds with familial erythermalgia and found a linkage to chromosomal arm 2q.[11] Novel mutations of voltage-gated sodium channels that are selectively expressed in peripheral nerves have been discovered.[12, 13, 14, 15]

Han et al, in a study investigating whether a genotype-phenotype association exists in early- and late-onset inherited erythromelalgia, found a shift in the patient’s mutation hyperpolarization activation that was smaller than that seen in early-onset disease mutations but similar to another mutation associated with late-onset inherited erythromelalgia.[16]  The test was done by conducting a voltage-clamp and current-clamp analysis of a new sodium channel Na(v)1.7 mutation, Q10R, in a patient who presented with erythromelalgia in the second decade.[16] With current-clamp analysis, Q10r expression induced hyperexcitability in dorsal root ganglion neurons, but the increase in excitability was smaller than that produced by a mutation in early-onset disease. Han et al suggested that their findings reflected a genotype-phenotype relation at the clinical, cellular, and molecular/ion channel levels in inherited erythromelalgia; mutations that produce smaller effects on sodium channel activation appear to correlate with smaller degrees of dorsal ganglion root neuron excitability and later onset of clinical signs.[16]

Etiology

Primary erythromelalgia may be idiopathic or genetic in origin. Early-onset erythromelalgia can show a familial occurrence. Adult-onset erythromelalgia is idiopathic in the majority of cases, although an inherited case has been reported.[16] In the Mayo Clinic series, 3.6% of cases were familial.[17]

Hereditary erythromelalgia is an autosomal dominant disorder caused by gain-of-function mutations in SCN9A, which encodes a voltage-gated sodium channel, subtype Nav1.7.[11, 12, 13, 14, 15, 18] More than 20 SCN9A mutations have been reported in patients with primary erythromelalgia.[19]

Causes of secondary erythromelalgia include[2] :

Most reported cases of secondary erythromelalgia are due to myeloproliferative disorders with thrombocytosis (most commonly polycythemia vera or essential thrombocytosis). The actual prevalence of erythromelalgia in myeloproliferative disorders is uncertain.

In the Mayo Clinic series, only 9% of erythromelalgia cases were associated with myeloproliferative disorders.[17] In the Norwegian series, 19% of cases were associated with myeloproliferative disorders.[21]

Medications implicated in erythromelalgia include:

Zaza et al screened the World Health Organization pharmacovigilance database for drugs associated with erythromelalgia, to identify drugs that could possibly be repurposed for treatment of Raynaud phenomenon, and found 179 drugs associated with at least 1 case of erythromelalgia. The cluster of drugs with the highest Jaccard index stability consisted largely of calcium channel blockers, along with epoprostenol, alemtuzumab, and fumaric acid.[28]

Other disorders with a reported association with erythromelalgia include:

Whether the above associations are coincidental is not clear. In one patient with SLE, biopsy results showed vasculitis, and symptoms resolved with immunosuppressive therapy.[29]

Reports in Europe and Japan describe cases due to the ingestion of different species of Clitocybe mushrooms.[30, 31]

Epidemiology

United States statistics

Brown reported an incidence of one case per 40,000 patients at the Mayo Clinic in the 1930s. This rate overestimates the incidence in the general population; however, difficulty recognizing mild cases may cause an underestimation of the frequency of these conditions. Early-onset erythromelalgia (primary erythermalgia in the Drenth-Michiels classification) is rare, with fewer than 30 cases reported in the literature. In patients with myeloproliferative disorders, the reported prevalence of erythromelalgia is 3-65%.

International statistics

A case series from Norway shows data similar to that from the Mayo Clinic series.[21] In China, more than 70 outbreaks of epidemic erythromelalgia, with over 80,000 cases reported, have occurred since the mid-20th century; most have been reported between February and March and have coincided with a sharp temperature decline followed by a rapid temperature rise within a few days.[32, 20] A retrospective study in Sweden reported an incidence of 0.36 cases per 100,000 population.[33]

Age-related demographics

In early reports, the median age of onset of the early-onset form was 10 years. Adult-onset erythromelalgia has a wide age distribution, with most cases occurring in the fifth and sixth decades.

An analysis of 32 pediatric cases treated over a 37-year period at the Mayo Clinic concluded that the majority of cases are not inherited and that progress of the disease is variable. No safe or reliable treatment has been established, and erythromelalgia in the pediatric population is associated with substantial morbidity and, sometimes, death.[34]

In the Norwegian case series, patients were classified as having primary or secondary erythromelalgia.[21] The age range in the primary group (which could include patients with early-onset and idiopathic adult-onset disease) was 7-76 years, and the age range in the secondary group was 18-81 years. In the Mayo Clinic series, the median age was 60 years and the age range was 5-91 years.

Sex-related demographics

The early-onset (primary) form is reported to have a male-to-female ratio of 1:2.5. Secondary erythromelalgia was reported to have a male-to-female ratio of 3:2 in a review of 60 cases of erythromelalgia associated with myeloproliferative disorders.

The 1997 case series from Norway showed a female predominance (male-to-female ratio of 1:2), which included a variety of associated factors, of which only 19% were myeloproliferative disorders.[21] The Mayo Clinic series of 168 patients showed a male-to-female ratio of 1:3.[17]

Prognosis

A retrospective review of 168 patients with erythromelalgia examined at the Mayo Clinic between 1970 and 1994 showed a significant decrease in survival compared with that expected for age- and sex-matched control subjects.[17] However, a recent Swedish study that collected data retrospectively for a period of 10.5 years reported no mortality directly related to erythromelalgia, although three patients developed intra-abdominal malignancies on follow-up.[33]

Patients who respond to aspirin have little morbidity. Spontaneous remissions may occur. Early-onset disease is relatively unresponsive to treatment and generally is unremitting.

Patient Education

Patients with erythromelalgia should be aware that a multidisciplinary care team is beneficial to cater to the different aspects of erythromelalgia care. Examples of team members and their roles include:

Patients with erythromelalgia require education about the etiology, manifestations, and possible triggers of the disease. 

It is essential to inform patients about the association of erythromelalgia with myeloproliferative disorders and the need to undergo evaluation for such a potential underlying disorder. 

Follow-up with a provider familiar with erythromelalgia is important. An annual complete blood count with differential should be performed to monitor for signs of a developing myeloproliferative disorder.

History

The classic description of erythromelalgia is a triad of redness, pain, and warmth in the extremities, brought on by warming or dependency and relieved by cooling (see the image below).



View Image

Cardinal symptoms of erythromelalgia.

Paroxysmal burning pain has also been reported as a presenting symptom of erythromelalgia.[35] Erythromelalgia has rarely been reported to involve parts other than the extremities (eg, ears, face, genitals).[36, 37, 38]

Symptomatic episodes may last minutes to days. They often begin with an itching sensation and later progress to more severe pain with a burning quality. Pain may be so intense that the patient cannot walk; some must even keep their feet immersed in ice water.

The lower extremities are affected more often than the upper extremities. The soles of feet and toes are most commonly involved. In rare cases, involvement may reach as high as the knees. Involvement is usually bilateral, though not necessarily symmetric. Warming the extremity or placing and maintaining the extremity in a dependent position can exacerbate symptoms; cooling and elevating the extremity can relieve symptoms.

Raynaud phenomenon has been reported to occur between episodes of erythromelalgia, but this may be coincidental.

In cases associated with a myeloproliferative disorder, erythromelalgia usually precedes the diagnosis of the myeloproliferative disorder by a median of 2.5 years. Rapid relief with aspirin is typical of this type of erythromelalgia and can be supportive diagnostically.

Given the association with myeloproliferative disorders, the clinician should inquire about other possible clinical manifestations of myeloproliferative disorders, such as:

Physical Examination

Between episodes, examination findings may be normal.

The affected extremity becomes warm and tender during an episode and appears dusky, red, and sometimes mottled.

Peripheral pulses may be normal or bounding. Acrocyanosis may be observed; rarely, it progresses to distal digital necrosis. Ischemic ulcers may be observed and may become infected secondarily.

Checking for splenomegaly and lymphadenopathy should be part of a comprehensive physical examination in a patient with suspected erythromelalgia.

Complications

Complications appear to be more frequent in patients who clearly have platelet-mediated disease.

Ulceration, necrosis, and gangrene of affected extremities are possible. Digital necrosis or skin ueration with secondary infection can lead to amputation. At least one patient had near-fatal hypothermia related to constant cooling required to control symptoms.

Histologic Findings

In patients with thrombocythemia, skin biopsy results have shown arteriolar endothelial cell swelling, with sparing of venules, capillaries, and nerves. Thickening of the vessel wall and narrowing of the lumen occur as a consequence of smooth muscle cell proliferation. Thickened arterioles may contain occlusive thrombi and ultimately may become fibrotic.

Biopsies from patients with primary erythromelalgia show mild mononuclear perivascular infiltrates with edema, thickened vascular basement membranes, and moderate endothelial swelling. The intimal thickening and thrombi seen in secondary erythromelalgia are lacking.

Laboratory Studies

A complete blood count (CBC) with differential should be obtained to search for evidence of a myeloproliferative disorder. In particular, it is important to look for a platelet count higher than 600 × 109/L (600 × 103 µg/L), a hematocrit greater than 50%, or an elevated granulocyte count (with all stages of maturation). Other laboratory results are nonspecific.

Imaging Studies

No specific findings are present on plain radiography of the feet and hands. Triple-phase technetium bone scanning is warranted for patients with a history of trauma or stroke and those in whom complex regional pain syndrome type 1 (reflex sympathetic dystrophy) is a strong possibility (particularly if the symptoms are unilateral).

Other Tests

Thermography reveals elevated skin temperatures in the affected areas, but this finding is not necessary to establish the diagnosis. Striking differences in surface temperature can occur between involved and uninvolved areas.

Approach Considerations

Evaluation and treatment can be conducted in an outpatient setting. Treatment is primarily medical and supportive. Local measures, such as cooling or elevating the extremity, may relieve symptoms. Avoid excessive warming or dependency of the extremity. The environment should be modified so that it is not too hot.

A number of topical and systemic medications have been used for treatment of erythromelalgia.[2] As current therapies provide only symptomatic relief, topical medications are generally preferred, in view of their more limited adverse effects.[40] Case reports describe successful use of spinal cord stimulation and ganglion stimulation and blocks.[41, 42, 43, 44]

With secondary erythromelalgia, treatment of the underlying disease process may lead to improvement or resolution of the erythromelalgia.[45] In patients with myeloproliferative disorders, chemotherapy to reduce the platelet count often alleviates symptoms, but it is not universally effective. Some patients with polycythemia vera have responded to phlebotomy. A hematologist may be consulted if an associated myeloproliferative disorder is present.

Surgery probably has no role in the management of erythromelalgia except to treat the rare complication of gangrene. Surgical sympathectomy has been attempted, with variable results.

No specific dietary restrictions are necessary. Vigorous exercise may induce an acute episode and should therefore be avoided.

Pharmacologic Therapy

[46] For primary erythromelalgia, the best therapy is unknown. A wide range of agents has been studied, including the following[38] :

Case reports of treatment with propranolol, epinephrine, biofeedback, sodium nitroprusside, nitroglycerin,[48] gabapentin,[49] typhoid vaccine, and topical oxymetazoline[46] appear in the literature, as well as case series with intravenous bupivacaine, and lidocaine plus mexiletine.[50]

Medications that affect voltage-gated sodium channels (eg, lidocaine and its oral form, mexiletine) show promise. In hereditary erythromelalgia, however, sensitivity to lidocaine may be determined by the patient's specific SCN9A genotype.[51, 52, 53, 38]

Prostacyclin may provide some benefit.[54]  In a pilot study of 12 patients, iloprost (a synthetic prostacyclin analogue) improved symptoms.[54]  A double-blind, crossover, placebo-compared study of the prostaglandin E1 analog misoprostol in 21 patients with erythromelalgia found that it reduces symptoms and microvascular arteriovenous shunting.[55]  

Topical therapy has been studied, including transdermal lidocaine.[56]  A study in 12 patients reported benefit with the alpha1-agonist midodrine, 0.2%, compounded in a moisturizing skin cream and applied topically three times a day during symptoms.[57]  Poterucha et al treated 36 patients with compounded topical amitriptyline-ketamine; 75% of those patients reported a reduction in pain.[58]

A Mayo Clinic study in 31 patients found that response to treatment with corticosteroids was more likely to occur in patients who reported a precipitant for their erythromelalgia (eg, surgery, trauma, or infection) and in those who had a subacute temporal profile to disease zenith (< 21 days). In addition, patients who responded to steroids started treatment sooner—at 3 (3-12) versus 24 (17-45) months (P = 0.003).[59]

In cases that are associated with other disorders, treating the original disease might improve symptoms. One case report described a patient with seronegative polyarthritis who developed erythromelalgia and was successfully treated with intravenous immunoglobulins.[60]

For erythromelalgia related to thrombocytosis, aspirin is usually the treatment of choice. Other nonsteroidal anti-inflammatory drugs (NSAIDs) provide relief of short duration. Anagrelide may be an alternative. Other platelet-inhibiting agents (eg, ticlopidine and dipyridamole) have no effect.

Monitor for complications, response to treatment, and development of a myeloproliferative disorder because erythromelalgia often precedes the clinical appearance of polycythemia vera or essential thrombocythemia.

Medication Summary

Platelet inhibition is helpful in patients with thrombocytosis. Aspirin is most often used, but anagrelide may also be effective.[61] The optimal pharmacologic therapy in primary erythromelalgia is still unknown.

Aspirin

Clinical Context:  Aspirin inhibits prostaglandin synthesis, which prevents formation of platelet-aggregating thromboxane A2.

Anagrelide (Agrylin)

Clinical Context:  Anagrelide may inhibit cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipase possibly by inhibiting phospholipase A2. A decrease in megakaryocyte hypermaturation may result in a reduction in platelet production.

Class Summary

Aspirin is preferred because it provides relief lasting longer than that of indomethacin or other nonsteroidal anti-inflammatory drugs (NSAIDs), presumably because of irreversible platelet inhibition.

What is erythromelalgia?What is the pathophysiology of erythromelalgia?What causes primary erythromelalgia?What causes secondary primary erythromelalgia?Which disorders are associated with erythromelalgia?What is the US prevalence of erythromelalgia?What is the global prevalence of erythromelalgia?Which age groups have the highest prevalence of erythromelalgia?What are the sexual predilections of erythromelalgia?What is the prognosis of erythromelalgia?Which clinical history findings are characteristic of erythromelalgia?Which physical findings are characteristic of erythromelalgia?Which conditions are included in the differential diagnoses of erythromelalgia?What are the differential diagnoses for Erythromelalgia?What is the role of lab tests in the workup of erythromelalgia?What is the role of imaging in the workup of erythromelalgia?What is the role of thermography in the workup of erythromelalgia?Which histologic findings are characteristic of erythromelalgia?How is erythromelalgia treated?What is the role of medications in the treatment of erythromelalgia?Which medications are used in the treatment of erythromelalgia?Which medications in the drug class Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are used in the treatment of Erythromelalgia?

Author

Drew H Barnes, MD, Fellow Physician, Hospice and Palliative Medicine, The Ohio State University Wexner Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Claudia M da Costa Dourado, MD, Clinical Assistant Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Program Director, Hematology and Medical Oncology Fellowship Program, Attending Physician, Division of Hematology and Medical Oncology, Department of Medicine, Einstein Medical Center Philadelphia

Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Disclosure: Nothing to disclose.

Additional Contributors

Ali T Taher, MD, PhD, FRCP, Professor of Medicine, Associate Chair of Research, Department of Internal Medicine, Division of Hematology/Oncology, Director of Research, NK Basile Cancer Center, American University of Beirut Medical Center, Lebanon

Disclosure: Nothing to disclose.

Antoine N Saliba, MD, Post-Doctoral Research Fellow, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

Robert J Nardino, MD Director, Internal Medicine Residency Program, Assistant Clinical Professor, Department of Internal Medicine, Hospital of Saint Raphael, Yale University School of Medicine

Robert J Nardino, MD is a member of the following medical societies: American College of Physicians, Association of Program Directors in Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Andrea LM Silber, MD Medical Oncologist, Father Michael J McGivney Center for Cancer Care, Saint Raphael Hospital

Andrea LM Silber, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine and American Society of Preventive Oncology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References

  1. Parker LK, Ponte C, Howell KJ, Ong VH, Denton CP, Schreiber BE. Clinical features and management of erythromelalgia: long term follow-up of 46 cases. Clin Exp Rheumatol. 2017 Jan-Feb. 35 (1):80-84. [View Abstract]
  2. Jha SK, Karna B, Goodman MB. Erythromelalgia. 2024 Jan. 47 (2):91-97. [View Abstract]
  3. Caldito EG, Kaul S, Caldito NG, Piette W, Mehta S. Erythromelalgia. Part I: Pathogenesis, clinical features, evaluation, and complications. J Am Acad Dermatol. 2024 Mar. 90 (3):453-462. [View Abstract]
  4. Drenth JP, van Genderen PJ, Michiels JJ. Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities. Angiology. 1994 Jun. 45(6):451-3. [View Abstract]
  5. Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985 Apr. 102(4):466-71. [View Abstract]
  6. Michiels JJ, Drenth JP, Van Genderen PJ. Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. 1995 Feb. 34(2):97-100. [View Abstract]
  7. Orstavik K, Weidner C, Schmidt R, et al. Pathological C-fibres in patients with a chronic painful condition. Brain. 2003 Mar. 126(Pt 3):567-78. [View Abstract]
  8. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003 May. 78(5):603-12. [View Abstract]
  9. Mork C, Kalgaard OM, Kvernebo K. Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol. 2002 Apr. 118(4):699-703. [View Abstract]
  10. Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol. 2005 Jun. 57(6):785-8.
  11. Drenth JP, te Morsche RH, Guillet G, et al. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol. 2005 Jun. 124(6):1333-8.
  12. Michiels JJ, te Morsche RH, Jansen JB, Drenth JP. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol. 2005 Oct. 62(10):1587-90.
  13. McDonnell A, Schulman B, Ali Z, Dib-Hajj SD, Brock F, Cobain S, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain. 2016 Apr. 139 (Pt 4):1052-65. [View Abstract]
  14. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004 Mar. 41(3):171-4. [View Abstract]
  15. Eberhardt M, Nakajima J, Klinger AB, Neacsu C, Hühne K, O'Reilly AO, et al. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J Biol Chem. 2014 Jan 24. 289(4):1971-80. [View Abstract]
  16. Han C, Dib-Hajj SD, Lin Z, Li Y, et al. Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain. 2009 Jul. 132:1711-22. [View Abstract]
  17. Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000 Mar. 136(3):330-6. [View Abstract]
  18. Deuis JR, Kumble S, Keramidas A, Ragnarsson L, Simons C, Pais L, et al. Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7). Hum Mol Genet. 2024 Jan 7. 33 (2):103-109. [View Abstract]
  19. Tang Z, Chen Z, Tang B, Jiang H. Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30. 10:127. [View Abstract]
  20. Zheng ZM, Zhang JH, Hu JM, et al. Poxviruses isolated from epidemic erythromelalgia in China. Lancet. 1988 Feb 6. 1(8580):296. [View Abstract]
  21. Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997 Sep. 242(3):191-7. [View Abstract]
  22. Dupont E, Illum F, Olivarius Bde F. Bromocriptine and erythromelalgia-like eruptions. Neurology. 1983 May. 33(5):670. [View Abstract]
  23. Bolzon A, Alessia Guidotti A, Alaibac MAS. Osimertinib‑induced erythromelalgia: A case report. Exp Ther Med. 2024 Jul. 28 (1):273. [View Abstract]
  24. Perez J, Khouri C, Park S, Imbert B, Cracowski JL. Eltrombopag-associated erythromelalgia in idiopathic thrombocytopenic purpura. Br J Dermatol. 2022 Mar. 186 (3):585-586. [View Abstract]
  25. Caiza-Zambrano F, Galarza J, Benetti M, Gonzalez F, Landriscina P, Reisin R, et al. Cyclosporine-induced erythromelalgia. Pract Neurol. 2023 Aug. 23 (4):343-345. [View Abstract]
  26. McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB, Tyagi A, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. J Am Acad Dermatol. 2022 Jan. 86 (1):113-121. [View Abstract]
  27. Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022 Feb. 36 (2):172-180. [View Abstract]
  28. Zaza P, Matthieu R, Jean-Luc C, Charles K. Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2020 Nov. 86 (11):2217-2222. [View Abstract]
  29. Drenth JP, Michiels JJ, van Joost T, Vuzevski VD. Secondary erythermalgia in systemic lupus erythematosus; [comment]. J Rheumatol. 1993 Jan. 20 (1):144-6. [View Abstract]
  30. Saviuc PF, Danel VC, Moreau PA, Guez DR, Claustre AM, Carpentier PH, et al. Erythromelalgia and mushroom poisoning. J Toxicol Clin Toxicol. 2001. 39 (4):403-7. [View Abstract]
  31. Nakajima N, Ueda M, Higashi N, Katayama Y. Erythromelalgia associated with Clitocybe acromelalga intoxication. Clin Toxicol (Phila). 2013 Jun. 51 (5):451-4. [View Abstract]
  32. Gu Y, Chen F, Liu T, Lv X, Shao Z, Lin H, et al. Early detection of an epidemic erythromelalgia outbreak using Baidu search data. Sci Rep. 2015 Jul 28. 5:12649. [View Abstract]
  33. Alhadad A, Wollmer P, Svensson A, Eriksson KF. Erythromelalgia: Incidence and clinical experience in a single centre in Sweden. Vasa. 2012 Jan. 41(1):43-8. [View Abstract]
  34. Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM. Pediatric erythromelalgia: A retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period. J Am Acad Dermatol. 2011 Jul 26. [View Abstract]
  35. Kondo T, Uehara T, Ikegami A, Ikusaka M. Paroxysmal burning pain caused by erythromelalgia. Lancet. 2014 May 10. 383(9929):1692. [View Abstract]
  36. Messeguer F, Agusti-Mejias A, Vilata Corell JJ, Requena C. Auricular erythromelalgia: report of a rare case. Dermatol Online J. 2013 Feb 15. 19(2):16. [View Abstract]
  37. Patel M, Femia AN, Eastham AB, Lin J, Canales AL, Vleugels RA. Facial erythromelalgia: a rare entity to consider in the differential diagnosis of connective tissue diseases. J Am Acad Dermatol. 2014 Dec. 71 (6):e250-1. [View Abstract]
  38. Tham SW, Giles M. Current pain management strategies for patients with erythromelalgia: a critical review. J Pain Res. 2018. 11:1689-1698. [View Abstract]
  39. Caldito EG, Caldito NG, Kaul S, Piette W, Mehta S. Erythromelalgia. Part II: Differential diagnoses and management. J Am Acad Dermatol. 2024 Mar. 90 (3):465-474. [View Abstract]
  40. Raef HS, Williams M, Fedeles F. Topical treatments for erythromelalgia. Dermatol Ther. 2022 Nov. 35 (11):e15860. [View Abstract]
  41. Hagedorn JM, Canzanello N, Lamer TJ. Dorsal Root Ganglion Stimulation for Erythromelalgia Related Foot Pain: A Case Report and Review of the Literature. Pain Pract. 2021 Jul. 21 (6):698-702. [View Abstract]
  42. Fan X, Bu H, Wen Y, Ma L, Huang C, Xu F, et al. Spinal Cord Stimulation in the Treatment of Pediatric Erythromelalgia. World Neurosurg. 2020 Oct. 142:388-390. [View Abstract]
  43. Ogawa S, Ueno H, Maruyama A, Amaya F. Extensive Lumbar Sympathetic Ganglion Block Combined With Epidural Block for Primary Erythromelalgia: A Case Report. A A Pract. 2020 Oct. 14 (12):e01325. [View Abstract]
  44. Lam CM, Zayed H, Sayed D. High frequency dorsal column spinal cord stimulation for management of erythromelalgia. BMJ Case Rep. 2021 Aug 5. 14 (8):[View Abstract]
  45. Jha SK, Karna B, Goodman MB. Erythromelalgia. 2021 Jan. [View Abstract]
  46. Altemir A, Iglesias-Sancho M, Barrabés-Torrella C, Sanchez-Regaña M, Salleras-Redonnet M. Successful treatment of knee erythromelalgia with topical oxymetazoline. Clin Exp Dermatol. 2022 Apr. 47 (4):778-780. [View Abstract]
  47. Cohen JS. High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother. 2002 Feb. 36(2):255-60. [View Abstract]
  48. Phong CH, Birmingham SW, Rojek NW. Erythromelalgia successfully treated with low-dose gabapentin in a pediatric patient. SAGE Open Med Case Rep. 2022. 10:2050313X221136768. [View Abstract]
  49. Feng S, He Z, Que L, Luo X, Liang L, Li D, et al. Primary erythromelalgia mainly manifested by hypertensive crisis: A case report and literature review. Front Pediatr. 2022. 10:796149. [View Abstract]
  50. Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, et al. Severe case and literature review of primary erythromelalgia: Novel SCN9A gene mutation. Vasc Med. 2011 Nov 9. [View Abstract]
  51. Legroux-Crespel E, Sassolas B, Guillet G, et al. [Treatment of familial erythermalgia with the association of lidocaine and mexiletine]. Ann Dermatol Venereol. 2003 Apr. 130(4):429-33. [View Abstract]
  52. Iqbal J, Bhat MI, Charoo BA, et al. Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. 2009 Jul-Aug. 29(4):316-8. [View Abstract]
  53. Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan. 153(1):80-5. [View Abstract]
  54. Kalgaard OM, Mork C, Kvernebo K. Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Derm Venereol. 2003. 83(6):442-4. [View Abstract]
  55. Mørk C, Salerud EG, Asker CL, Kvernebo K. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study. J Invest Dermatol. 2004 Mar. 122 (3):587-93. [View Abstract]
  56. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005 Oct. 141 (10):1320-1. [View Abstract]
  57. Davis MD, Morr CS, Warndahl RA, Sandroni P. Topically Applied Midodrine, 0.2%, an α1-Agonist, for the Treatment of Erythromelalgia. JAMA Dermatol. 2015 Sep 1. 151 (9):1025-6. [View Abstract]
  58. Poterucha TJ, Weiss WT, Warndahl RA, Rho RH, Sandroni P, Davis MD, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013 Mar. 12(3):308-10. [View Abstract]
  59. Pagani-Estévez GL, Sandroni P, Davis MD, Watson JC. Erythromelalgia: Identification of a corticosteroid-responsive subset. J Am Acad Dermatol. 2017 Mar. 76 (3):506-511.e1. [View Abstract]
  60. Moody S, Pacheco S, Butler IJ, Koenig MK. Secondary Erythromelalgia Successfully Treated With Intravenous Immunoglobulin. J Child Neurol. 2011 Dec 7. [View Abstract]
  61. Aruch D, Mascarenhas J. Contemporary approach to essential thrombocythemia and polycythemia vera. Curr Opin Hematol. 2016 Mar. 23 (2):150-60. [View Abstract]

Cardinal symptoms of erythromelalgia.

Cardinal symptoms of erythromelalgia.